Kymera Therapeutics, Inc. (KYMR)

71.00 -7.42 (-9.46%) At close: 4:00PM EST

Kymera Therapeutics, Inc.

200 Arsenal Yards Boulevard
Suite 230
Watertown, MA 02472
United States
857-285-5300
http://www.kymeratx.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 64

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Nello Mainolfi M.D., Ph.D.	Co-Founder, Pres, CEO & Director	504.53k	N/A	1978
Mr. Bruce N. Jacobs CFA	Chief Financial Officer	404.36k	N/A	N/A
Dr. Jared A. Gollob	Chief Medical Officer	458.29k	N/A	1964
Dr. Bruce L. Booth Ph.D., D.Phil.	Co-Founder & Chairman	N/A	N/A	1974
Mr. Brian Albarran M.B.A., Ph.D.	VP of Strategy & Operations	N/A	N/A	N/A
Mr. Michael J. Todisco	VP of Accounting & Fin.	N/A	N/A	1965
Dr. Richard Chesworth Ph.D.	Chief Scientific Officer	N/A	N/A	1970
Mr. Paul Cox	VP of Investor Relations & Communications	N/A	N/A	N/A
Ms. Paige Cochran	VP of HR	N/A	N/A	N/A
Dr. Mark E. Nuttall Ph.D.	Chief Bus. Officer	N/A	N/A	N/A

Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; and STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases. The company was founded in 2015 and is headquartered in Watertown, Massachusetts.

Corporate Governance

Kymera Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.